Recruitment to the COLOSSUS translational study will be closing at the end of September 2021. The purpose of the COLOSSUS study is to identify new biomarkers and classifiers for microsatellite stable RAS mutated colorectal cancer. The aim is to develop new diagnostics and therapeutic options for patients bearing this type of cancer after they develop resistance to the current standard of care, and for whom there are no further treatment options currently available.
We wish to acknowledge and thank the ten clinical sites involved:
In Ireland,
- University Hospital Limerick
- Bon Secours Hospital Cork
- Tallaght University Hospital, Dublin
- Vincent’s University Hospital, Dublin
- Beaumont Hospital, Dublin
In Germany:
- University Hospital Mannheim
- Onkologische Schwerpunktpraxis Speyer
- Onkologische Schwerpunktpraxis Heidelberg
And the two Spanish hospitals:
- Hospital Universitari Vall d’Hebron, Barcelona
- Institut Catala d’Oncologia; L’Hospitalet de Llobregat, Barcelona.
A special thanks to our partners at Cancer Trials Ireland for coordinating the international COLOSSUS study.
We are very pleased with how recruitment has picked up over recent months and we have reached our targets.